Endocrine Abstracts

Relacorilant is a highly selective glucocorticoid receptor modulator that antagonizes the effects of excess cortisol while showing no significant affinity for the mineralocorticoid and progesterone receptors. In a Phase 2 study in patients with endogenous hypercortisolism, relacorilant demonstrated improvements in glycemic and hypertension control with no treatment-related hypokalemia or antiprogesterone effects. An international, multicenter, Phase 3 clinical trial, using ran...

Background: Relacorilant is a highly selective glucocorticoid receptor (GR) modulator in development for the treatment of endogenous Cushing syndrome (CS). Unlike the GR antagonist mifepristone, relacorilant lacks affinity for the progesterone and other receptors. In a phase 2 study in patients with CS (Pivonello et al, 2021), relacorilant provided clinically meaningful changes in several cortisol-excess-related comorbidities, including hypertension and hyperglycemia,...

In patients with Cushing syndrome (CS), hypercoagulability represents a significant concern, leading to elevated risk for thrombotic events. After curative surgery, hypercoagulability persists for several months; CS treatment guidelines recommend anticoagulation therapy for ≤ 3 months. In patients with Cushing disease, hemostatic parameters may even worsen after surgery, independent of surgical outcome; improvements begin ~3 months after successful surgery (Casonato ...

Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...